Back to search results

Study of Pirtobrutinib, Venetoclax, and Obinutuzumab for CLL or Richter Transformation

This study is looking at a combination of three drugs: pirtobrutinib, venetoclax, and obinutuzumab. These drugs are given to people with chronic lymphocytic leukemia (CLL) or Richter transformation (RT) who have not had treatment before. The main goal is to see how safe this combination is and how well it works to reduce the cancer. Researchers will measure how many patients have very low levels of cancer cells after treatment. You may be able to join if you are at least 18 years old and have CLL/SLL that needs treatment, or if you have RT that has not been treated before or has come back.

Study design
This is an interventional study planning to enroll 60 participants. It will test the effects of combining pirtobrutinib, venetoclax, and obinutuzumab.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The severity of side effects will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05536349

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting
PHASE2Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~60 participants
Updated 2026-04-30 on ClinicalTrials.gov
What's tested:PirtobrutinibObinutuzumabVenetoclaxValacyclovirAllopurinol

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The severity of the adverse events (AEs) will be graded according to the U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0.
Measured over through study completion an average of 1 year.

Conditions

Leukemia

Explore related trials

Chronic Lymphocytic LeukemiaRichter Syndrome

NCT05536349

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • M D Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Nitin Jain, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Nitin Jain, MD
[email protected]
(713) 745-6080
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • The severity of the adverse events (AEs) will be graded according to the U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0.through study completion an average of 1 year.